Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma

Tanimoto Tetsuya; Oshima Kumi; Tsuda Kenji; Mori Jinichi; Shimmura Hiroaki

首页> 外文期刊>The lancet oncology >Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma

【24h】

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma

机译：Rituximab和用于高风险弥漫性大B细胞淋巴瘤的自体干细胞移植

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2017年第10期|共1页
作者
Tanimoto Tetsuya; Oshima Kumi; Tsuda Kenji; Mori Jinichi; Shimmura Hiroaki;
展开▼
作者单位

Jyoban Hosp Tokiwa Fdn Dept Internal Med Fukushima 9728322 Japan;

Jyoban Hosp Tokiwa Fdn Dept Internal Med Fukushima 9728322 Japan;

Teikyo Univ Chiba Med Ctr Dept Haematol &

Rheumatol Chiba Japan;

Jyoban Hosp Tokiwa Fdn Dept Internal Med Fukushima 9728322 Japan;

Jyoban Hosp Tokiwa Fdn Dept Urol Fukushima 9728322 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study [J] . Chiappella Annalisa, Martelli Maurizio, Angelucci Emanuele, The lancet oncology . 2017,第8期

机译：有或没有高剂量化疗的rituximab-剂量 - 致密化疗加上高风险弥漫性大B细胞淋巴瘤（DLCL04）中的自体干细胞移植：多期，开放标签，随机，控制，第3期研究的最终结果
2. Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma [J] . Tanimoto Tetsuya, Oshima Kumi, Tsuda Kenji, The lancet oncology . 2017,第10期

机译：Rituximab和用于高风险弥漫性大B细胞淋巴瘤的自体干细胞移植
3. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study [J] . Chiappella Annalisa, Martelli Maurizio, Angelucci Emanuele, Journal of Turbulence . 2017,第8期

机译：有或没有高剂量化疗的rituximab-剂量 - 致密化疗加上高风险弥漫性大B细胞淋巴瘤（DLCL04）中的自体干细胞移植：多期，开放标签，随机，控制，第3期研究的最终结果
4. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma [C] . Bohua Li, Hao Wang, Yajun Guo, International conference of molecular simulations and applied informatics technologies . 2012

机译：具有抗利妥昔单抗的B细胞淋巴瘤的有效抗肿瘤活性的利妥昔单抗变体的表征
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma [O] . Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, -1

机译：CD20 +弥漫性大B细胞淋巴瘤复发患者自体干细胞移植后的利妥昔单抗维持治疗：复发性侵袭性淋巴瘤合作试验的最终分析
7. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): Final results of a multicentre, open-label, randomised, controlled, phase 3 study [O] . Chiappella Annalisa, Martelli Maurizio, Angelucci Emanuele, 2017

机译：高危弥漫性大B细胞淋巴瘤（DLCL04）联合利妥昔单抗大剂量化疗加或不加大剂量化疗加自体干细胞移植：一项多中心，开放标签，随机，对照，3期研究的最终结果

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma

著录项

相似文献

相关主题

期刊订阅